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Abstract: Epidemiologic and clinical changes in the HIV epidemic over time have presented a challenge to public health 
surveillance to monitor behavioral and clinical factors that affect disease progression and HIV transmission. The Medical 
Monitoring Project (MMP) is a supplemental surveillance project designed to provide representative, population-based 
data on clinical status, care, outcomes, and behaviors of HIV-infected persons receiving care at the national level. We 
describe a three-stage probability sampling method that provides both nationally and state-level representative estimates. 
In stage-I, 20 states, which included 6 separately funded cities/counties, were selected using probability proportional to 
size (PPS) sampling. PPS sampling was also used in stage-II to select facilities for participation in each of the 26 funded 
areas. In stage-III, patients were randomly selected from sampled facilities in a manner that maximized the possibility of 
having overall equal selection probabilities for every patient in the state or city/county. The sampling methods for MMP 
could be adapted to other research projects at national or sub-national levels to monitor populations of interest or evaluate 
outcomes and care for a range of specific diseases or conditions. 
Keywords: HIV, sampling, representative, surveillance. 
INTRODUCTION 
 The HIV epidemic is dynamic: during the years since the 
first cases were reported, it has been characterized by both 
epidemiological and clinical instability, as the disease spread 
rapidly, infected different populations, responded to 
treatment and was associated with a changing spectrum of 
opportunistic illnesses. Surveillance is an essential element 
in monitoring and planning responses to important diseases 
with such characteristics, and that is certainly the case for 
HIV. A challenge to public health is to determine how to 
conduct such surveillance to best answer questions about the 
status of the disease and its impact, given the changes that 
have occurred in disease spectrum, populations affected, and 
social correlates of the illness and its spread. Such 
surveillance also is highly relevant to the challenges in 
reforming the health care system. The comparative 
effectiveness of systems for delivering acute, chronic and 
preventive services is best understood in the context of the 
care that is provided in the full breadth of settings and 
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systems, and to the full range of populations using such 
services. 
 AIDS has been reportable throughout the United States 
since the onset of the HIV epidemic, and both AIDS and 
HIV have been reportable in recent years [1]. The resulting 
core information is invaluable, but insufficient [2]. In 
response, the Centers for Disease Control and Prevention 
(CDC) has conducted a number of secondary surveillance 
studies. These were generally unlinked medical record and 
interview studies conducted in a relatively small number of 
urban sites. Though these studies provided much clinical and 
behavioral detail, they did not meet the growing need for 
integrated, representative, population-based data on clinical 
status, care, outcomes, and behaviors at the national level. 
The Medical Monitoring Project (MMP) is a CDC-sponsored 
supplemental surveillance project that is designed to meet 
that need by combining interviews with medical record 
abstractions from patients selected using nationally 
representative scientific probability sampling. 
 In this paper we describe a sampling strategy that 
provides both nationally representative estimates as well as 
estimates at the state level. These state level estimates cover 
virtually all large states as well as a sampling of smaller 
states. The strategy outlined in this paper (to provide both 
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national and selected state estimates) provides a 
methodological model that may be applied to the study of 
other low incidence diseases in the United States as well as 
similar diseases in other countries. The sampling strategy 
described is somewhat different from more traditional 
probability sampling models for national estimates, where 
typically, primary sampling units consist of individual 
counties and metropolitan areas. However, the use of states 
as primary sampling units was consistent with the funding 
and data collection model. It also provided participating 
states with the direct benefit of having the ability to obtain 
valid state level estimates. 
Probability Sampling 
The Rationale 
 The goal of probability sampling is to generate unbiased 
estimates by developing a sample that accurately represents 
the whole target population rather than a subset selected 
according to some sort of rule. A probability sample is one in 
which each person in the target population has some 
probability of selection and in which the probability of 
selection is known for each person who is actually selected. 
That is, no person of interest is excluded and the number of 
people represented by each selected person is known.
1
 
Because of its ability to represent an entire population of 
interest, probability sampling is the method of choice for 
producing valid and unbiased statistical estimates for large 
populations and their subgroups. 
Single Stage vs Multistage Probability Sampling 
 The simplest way of accomplishing a probability sample 
is a one-step process, or one stage sampling, by making 
random picks directly from a sampling frame containing a 
complete and current listing of all the persons in the 
population. However, this is impractical for most large 
populations, because it would result in a geographically 
dispersed sample which is difficult and expensive to 
implement. In addition, a complete and current list of 
population elements, such as HIV infected persons in care, 
may not be available. Fortunately, the construction of such a 
list is not required in order to develop a probability sample. 
Sampling can be accomplished by constructing a probability 
sample in stages, i.e., by making a series of random picks 
from each of a hierarchical series of sampling frames (e.g., 
geographic areas, health care providers, patients); these picks 
must be made in such a way that each selection is linked to a 
selection made in the previous sampling stage by virtue of 
having the frame for that pick be defined by the elements 
included in the previous selection. 
 The HIV Cost and Services Utilization Study (HCSUS) 
used a multistage probability sample of persons in care for 
HIV disease in the 48 contiguous United States in 1996, 
demonstrating that such an approach is feasible for studying 
HIV disease [3]. In the HCSUS, the hierarchy was as 
follows: 1) participants were selected from a complete list of 
patients being cared for by their provider, 2) providers were 
selected from a complete list of providers in their area, and 
3) areas were selected from a complete list of all such areas 
in the United States. The MMP uses many of the features of 
                                                           
1The inverse of the probability of selection for a sampled person is the 
number of persons in the population represented by that sampled person. 
the HCSUS sample design in developing a nationally 
representative probability sample of non-institutionalized 
persons receiving outpatient care for HIV infection in the 50 
United States, the District of Columbia and Puerto Rico. 
THE STRATEGY FOR DEVELOPMENT OF THE 
PROBABILITY SAMPLE IN MMP 
 For MMP, the population of interest is defined as all 
persons who are HIV-positive and have received any 
medical care from a known outpatient provider of HIV care 
during a specified period of time. We refer to this time 
period as the Population Definition Period (PDP). 
 The sample was selected in three stages. The overall 
approach is to randomly select from the sampling frames at 
each stage using probability proportional to size (PPS) 
sampling at all but the last stage. This method sets the 
selection probability for each unit according to the relative 
size of that unit: the larger the unit, the greater the 
probability of it being selected. This allows the calculation of 
selection probabilities in the last stage such that the overall 
probability of selection for each person in the sample is 
similar. This is desirable because each participant’s data is 
similarly weighted, which is the most efficient circumstance. 
 The stage-I sampling frame consisted of 52 primary 
sampling units (PSUs): the 50 United States, the District of 
Columbia, and Puerto Rico. Twenty of these 52 PSUs were 
selected using geographic stratification and probabilities 
proportional to the estimated number of persons living with 
AIDS at the end of 2002. Eighty-one percent of all reported 
AIDS cases had been reported from those areas. Stage-II 
sampling frames were developed separately for the selected 
PSUs using a variety of appropriate methods. Six cities or 
counties reside within five of the 20 selected states but were 
considered separately in stage II (because their funding for 
HIV/AIDS surveillance activities, including MMP, is 
separate from that of the states in which they are situated). 
For these five states, the different funding areas may be 
thought of as separate sampling strata, each with its own 
second stage sampling frames. Thus, there are a total of 26 
sampling strata, with corresponding frames. In each of these 
selected areas or frames, local MMP staff developed a 
comprehensive list of all outpatient facilities that manage 
HIV patients. 
 An outpatient facility was defined as any hospital-based 
or stand-alone clinic or health care facility, any group or 
private practice, or any grouping of these entities in which 
medical records or a medical record system is shared. 
Emergency departments and inpatient facilities were 
excluded from the facility sampling frames, and thus from 
MMP. Second-stage sampling was random with the 
probability of selection proportionate to size in 19 of the 20 
PSUs and the 6 separately funded areas. In the other PSU 
(Delaware), a census of 21 facilities was necessary to obtain 
the minimum number of patients needed. Stage II resulted in 
the selection of 25 to 68 (mean = 41) facilities in each state 
or separately funded area. 
 The stage-III sampling frames were developed separately 
for each of the selected facilities. Frames consist of 
comprehensive listings of persons with known HIV infection 
who made at least one visit to one or more of the sampled 
facilities during the PDP. Selections were random and were 
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performed in such a way as to maximize the possibility of 
having equivalent overall probabilities of selection for every 
patient in the project area (state or city/county), and with 
overall sampling rates calculated to obtain 10,000 selections 
overall and a minimum of 400 persons in each of the 20 
PSUs. 
 This design ensures that each person in the population is 
given a non-zero probability of selection into the sample. It 
results in a valid probability sample because each element 
(member) of the target population is associated with a unit 
(facility) in the secondary sampling frame, and each of these 
is associated with a PSU. 
FIRST STAGE OF SAMPLING 
 In most multistage probability samples, the first stage 
sampling units are defined so the resulting first stage sample 
comprises 20% or less of the defined units. In MMP, the 
percentage is much higher because there were a smaller 
number of PSUs. The decision to define a small number was 
driven largely by the MMP funding model. Under CDC 
Program Announcement 04155, entities eligible to receive 
funding for MMP were the 50 states, the District of 
Columbia, Puerto Rico, and the six cities/counties that 
receive separate funding for HIV/AIDS surveillance. 
Identifying and Stratifying the Primary Sampling Units 
 The separately funded cities/counties are Chicago, IL; 
Houston, TX; Los Angeles County, CA; New York City, 
NY; Philadelphia, PA; and San Francisco, CA. The decision 
not to directly pick these cities was driven by a secondary 
goal of providing statewide data to participating state health 
departments. This was accomplished by folding the six 
cities/counties into the five states that contain them for the 
purposes of first stage sampling only (i.e., not for purposes 
of administering the project). This yielded 52 PSUs. The 
decision to sample 20 of the 52 PSUs was made based on 
funding availability and face validity rather than on any 
statistical argument. 
 In MMP, a systematic sampling with a random start was 
used to generate a random stratified proportional to size 
sample. In order to improve the reliability of the final 
sample, the PSUs were stratified into five groups - four 
geographic and one by size, then ordered by the PSU’s 
measure of size (MOS). The MOS is an estimate of the 
number of persons in the population of interest that are 
contained in each unit of a sampling frame. For the first 
stage of MMP, the MOS were the CDC estimates of the 
number of adults and children living with AIDS at the end of 
2002, current as of November 24, 2003. Although the target 
population for MMP is all persons diagnosed with HIV in 
care in the US, at the time the first stage was developed, 
there was no data system that collected information on HIV 
infected persons in care. Therefore, the estimated number of 
persons living with AIDS was used as a proxy measure of 
PSU size. 
 The systematic sampling procedure was as follows. We 
first created a list or pseudo-population of patients grouped 
by PSUs, arrayed by stratum and size. For example, if the 
largest PSU in the first stratum (PSU #1) had 1000 cases, 
then patients 1 to 1000 would be labeled “PSU #1;” and if 
PSU #2 had 2130 cases, then patients 1001 to 3130 would be 
labeled “PSU #2.” 
Selecting the Sample of States 
 Selection proceeds by picking a random start at the 
beginning of the list and then taking uniform steps forward 
through it. In MMP, the initial pick was to be a patient in the 
first 5% of the list with subsequent steps each being 5% 
forward through the list; 5% having been chosen because we 
wished to sample 20 PSUs. The PSU containing each patient 
picked in this procedure is included. Since the steps each 
contain 5% of the total cases, at least one step must fall 
among the patients that represent any PSU that has more 
than 5% of the total cases. These large PSUs are sampled 
with certainty. The process is iterative. The cases in certainty 
PSUs are removed, the step size recalculated based on the 
number of available and required PSUs, and the additional 
PSUs to be sampled with certainty are identified and 
removed. The cycle repeats until no further PSUs were 
sampled with certainty. 
 Describing the particular choices made in the MMP 
sample will elucidate this approach. The total number of 
cases, that is, the sum of the MOS, across all 52 PSUs was 
384,070. Five percent of this total is 19,204. Thus any PSU 
with at least 19,204 cases was to be sampled with certainty. 
Four PSUs had at least this many cases: California, Florida, 
New York, and Texas (Table 1). 
 We then excluded the four certainty PSUs, recalculated 
the total number of cases, and redefined the criteria for PSUs 
that would also be sampled with certainty. Sixteen PSUs 
remained to be sampled from 48 remaining PSUs. So, any 
PSU with at least 6.25%, or 12,473 of the remaining 199,569 
cases, was to be sampled with certainty. Four PSUs had at 
least this many cases: Georgia, Illinois, New Jersey and 
Pennsylvania. Twelve PSUs remained to be sampled from 
the remaining 44 PSUs. So, any PSU containing at least 
8.3%, or 11,860 of the remaining 142,321 cases was to be 
sampled with certainty. No PSUs contained this many cases, 
so no further PSUs were sampled with certainty. 
 The remaining 12 PSUs were to be sampled PPS in a 
stratified manner. This was accomplished by recreating the 
list according to stratum and size as described above, using 
the cases from the remaining 44 PSUs. Selecting randomly 
from such as list results in a sample that is: a) PPS because 
the proportion of entries that are grouped under a PSU 
reflects the proportion of cases contained in that PSU, and b) 
stratified because of the specific ordering. 
 We grouped the states into five strata: four based on 
region and one that grouped together states with few cases. 
The stratum of states with few cases was formed to minimize 
how many PSUs with few cases were included. Sampling 
cases from PSUs that contain very few cases is difficult and 
expensive to implement, so we defined a stratum of “small” 
PSUs in such a way that only one PSU would be sampled 
from that stratum. Since 12 PSUs were to be sampled, a 
stratum containing PSUs with close to but less than the 
“step” value of 8.3% (11,860) of all cases would likely 
contribute one PSU but could not contribute two or more to 
the sample. To define this stratum, the smallest PSU was 
chosen and PSUs were added from the list (taking the next 
smallest and so on) until the total number of included cases 
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was smaller than 11,860 but as large as possible. In this 
manner, 18 PSUs containing 11,118 were chosen for the 
small state stratum; adding the next smallest would have 
resulted in 12,915 cases in this stratum. 
 The remaining 26 PSUs (defined as “medium” size) were 
divided into four geographical strata based on the Census 
definitions of geographic regions: the Northeast region 
contained Census divisions New England and Middle Atlantic 
(states: CT, MA); Midwest contained Census divisions East 
North Central and West North Central (states: WI, MN, IN, 
MO, MI, OH); South contained Census divisions South 
Atlantic, East South Central and West South Central as well as 
Puerto Rico (states: AR, OK, KY, MS, AL, TN, SC, LA, NC, 
VA, DC, MD, PR); and West contained Census divisions 
Mountain and Pacific (states: OR, NV, CO, AZ, WA). 
 The geographic strata were ordered: Northeast, Midwest, 
South and West and then were followed by the small PSU 
stratum to form the pseudo population list. Within each stratum, 
the PSUs were ordered by size. In order to preclude possible 
sampling periodicity by size, within Northeast the PSUs were 
ordered smallest to largest; within Midwest largest to smallest; 
within South smallest to largest; within West largest to smallest; 
and within the small PSU stratum smallest to largest. The 
sampling frame resulting from the determination of the certainty 
picks, and from the stratification and ordering of the remaining 
PSUs, is shown in Table 1. 
 PSUs eligible to be one of 12 picked by random PPS 
selection are listed after the certainty PSUs, beginning with 
Connecticut. As implied above, the initial pick had to be within 
the first 8.3% or 11,860 cases. A random number of 0.878 was 
chosen, thus identifying a random start of 0.878 x 11,860, or 
10,413. Case number 10,413 is contained within Massachusetts, 
which therefore was the first randomly selected PSU. Stepping 
though the list at intervals of 11,860 resulted in the selection of 
one state in the Northeast, two each in the Midwest and the 
West, six in the South and, as anticipated, one from the 
grouping of states with few cases. Areas with “Yes” in the 
Sampled column in Table 1 comprise the final sample of states. 
SECOND STAGE OF SAMPLING 
 The purpose of the second-stage sampling was to select 
facilities within the project areas. Although 20 PSUs were 
selected in the first stage of sampling, there were 26 project 
areas, as noted above, including the six cities/counties that are 
funded and administered separately in five of the 20 selected 
PSUs. 
 A facility sampling frame was developed individually in 
each of the 26 project areas. An eligible facility was defined as 
one known to provide HIV care, which was defined as having 
providers who prescribe antiretroviral therapy or order CD4 or 
HIV viral load tests. Providers who referred patients to other 
providers rather than managing their HIV medical care were not 
included in the facility sampling frame. 
Constructing the Facility Sampling Frame 
 A variety of sources were used to identify facilities 
providing HIV care (including the number of individuals in 
care at those institutions). These included the HIV/AIDS 
Reporting System (HARS) databases, laboratory reporting  
 
databases and other local databases, including AIDS Drug 
Assistance Program and Medicaid databases. The HARS was 
the best source for identifying HIV care providers. It is the 
current version of the reporting system that all states have 
used for surveillance of new AIDS cases since 1985 and, 
since at least 2005, all new cases of HIV infection [4,5]. In 
2005, when the first facility sampling frames were 
constructed, 18 of the 20 states conducting MMP had HIV 
viral load and/or CD4 reporting of any value or of all tests 
performed. 
 For the 2005 pilot data collection cycle, the following 
types of facilities were included on the facility sampling 
frame: outpatient and inpatient care facilities; Veterans 
Administration facilities; and state or local prisons and jails 
that met the definition of providing HIV care. The following 
types of facilities were not included: emergency departments 
(because they do not provide sufficient information on the 
standard of care), HIV counseling and testing sites and 
laboratories (which report HIV infection, but do not provide 
medical care for HIV infection), Federal prisons, military 
bases and institutions (project areas have no jurisdiction to 
obtain their medical records), and pediatric facilities (unless 
they provided HIV medical care to persons age 18 and 
older). 
 For the 2007 and subsequent data collection cycles, two 
other exclusions were made from the facility sampling frame 
to focus predominately on patients receiving outpatient care. 
It was decided not to include inpatient facilities or prisons or 
jails on the facility sampling frame. Inpatient facilities were 
excluded since they do not provide primary medical care for 
HIV infection. HIV-infected patients could have interfaced 
with inpatient care facilities for a variety of reasons. It would 
be prohibitively difficult to recruit providers who do not 
typically provide HIV care (but who may have prescribed 
antiretroviral medications or ordered CD4 counts or HIV 
viral load tests during the patient’s inpatient stay). In 
addition, the likelihood of finding and recruiting patients 
who had only one encounter with the provider at an inpatient 
facility would be much lower than that for patients who have 
an ongoing relationship with a regular HIV care provider. In 
some instances, such as hospice or care in long term care 
facilities, primary medical care is provided; however, this 
care is different from outpatient care provided by other 
facilities on the facility sampling frame. Prisons and jails as 
providers of HIV care were excluded from the sampling 
frame because these facilities are not able to be accessed in 
all project areas due to Institutional Review Board (IRB) and 
other issues. 
 Once the lists of facilities from HARS and each of the 
supplemental sources were obtained, cleaned, and 
standardized, they were combined into a single facility 
sampling frame (FSF) for each project area, on which each 
facility only appears only once. Any outpatient facility that  
met the MMP facility definition and was a known provider 
of HIV medical care during the recent time periods used for 
each data source was eligible to be included on the 
FSF.Facilities that had not seen a patient with HIV during 
the time frame estimated patient loads (EPLs) were obtained 
(i.e., they had an EPL of 0) were included on the FSF, but 
patients were not sampled from these facilities. 
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Table 1. Sampling Frame of States, with Region, Measure of Size, Stratum, and Sample Indicator 
 
Area of Residence  Measure of Size Region* PSU Stratum Size Sampled 
NEW YORK  63412 NE Large (certainty) Yes 
FLORIDA  41015 S  Large (certainty) Yes 
TEXAS  27358 S  Large (certainty) Yes 
CALIFORNIA  52716 W  Large (certainty) Yes 
NEW JERSEY  15485 NE  Large (certainty) Yes 
PENNSYLVANIA  15362 NE  Large (certainty) Yes 
ILLINOIS  13718 MW  Large (certainty) Yes 
GEORGIA  12683 S  Large (certainty) Yes 
CONNECTICUT 6579 NE Medium No 
MASSACHUSETTS  8025 NE Medium Yes 
OHIO  5978 MW Medium No 
MICHIGAN  5395 MW Medium Yes 
MISSOURI  4838 MW Medium No 
INDIANA  3429 MW Medium Yes 
MINNESOTA 1818 MW Medium No 
WISCONSIN 1797 MW Medium No 
ARKANSAS 1837 S Medium No 
OKLAHOMA 1908 S Medium No 
KENTUCKY 2150 S Medium No 
MISSISSIPPI 2602 S Medium Yes 
ALABAMA 3660 S Medium No 
TENNESSEE 5639 S Medium No 
SOUTH CAROLINA 5863 S Medium Yes 
LOUISIANA 6902 S Medium No 
NORTH CAROLINA 7128 S Medium Yes 
VIRGINIA 7443 S Medium Yes 
DISTRICT OF COLUMBIA 8234 S Medium No 
PUERTO RICO 10560 S Medium Yes 
MARYLAND 11798 S Medium Yes 
WASHINGTON 4889 W Medium Yes 
ARIZONA 4316 W Medium No 
COLORADO 3465 W Medium No 
NEVADA 2502 W Medium No 
OREGON 2448 W Medium Yes 
NORTH DAKOTA 47 MW Small No 
WYOMING 91 W Small No 
SOUTH DAKOTA 99 MW Small No 
MONTANA 181 W Small No 
VERMONT 236 NE Small No 
ALASKA 252 W Small No 
IDAHO 262 W Small No 
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 Facilities are sampled in the second stage in a manner 
analogous to the PSUs in the first stage. To accomplish PPS 
sampling at this stage, an EPL of adult HIV infected patients 
in each facility was also needed on the frame. The EPL is an 
estimate of the actual number of eligible patients that will be 
seen at a facility during the PDP for a given data collection 
cycle. In 2007, for each data source from which EPLs could 
be derived, a 4 month EPL was created using the most recent 
data from each data source as well as from facility contacts 
to accurately reflect the patient load for the January 1 
through April 30, 2007 PDP. Data were obtained either from 
a data run or other record-based source or as a less precise 
estimate, typically provided by facility staff. A matrix, or 
table, of EPLs from each data source was constructed for all 
eligible facilities, and this matrix was used to create the FSF, 
which in turn was used to select facilities for the previous 
data collection cycles. During this step, the quality of the 
different EPLs obtained across the various data sources was 
evaluated in order to determine, for each facility, which EPL 
was the most accurate to use for facility sampling. 
Facility Linkage 
 A sampled patient’s overall selection probability is the 
product of the three stage-specific selection probabilities. It 
is desirable that this overall probability of selection be 
uniform. Such uniformity will result in greater statistical 
efficiency because there would be minimal variation in point 
estimates derived from the information that patients 
contributed. The result is that confidence limits for estimates 
derived from MMP data will thus be minimized. Facilities 
with very low EPLs, or small facilities, are problematic in 
this regard because achieving uniform selection probability 
may require the selection of more patients than they actually 
have. In MMP, this was handled by linking known small 
facilities to larger ones to create linked ‘facilities’ with 
combined EPLs that met or exceeded a minimum value. 
 Facilities designated as small were linked to one or more 
other facilities so that the small facility is selected for the 
sample only if the facilities to which it is linked also are 
selected. The desired minimum EPL across each project area 
ranges between 40 and 80, and depend in part on the 
distribution of EPLs across the entire FSF for that project 
area. Minimum values of 40 to 80 have been determined to 
be optimal for selecting the facility sample across project 
areas based on anticipated design effects and distributions of 
facility sizes. 
 In project areas of large geographic size, or with 
variations in facility attributes by region, this linkage was 
performed within pre-specified sub-regions to facilitate 
efficient use of project area resources during data collection, 
as well as to ensure facilities from every sub-region were 
selected. 
Selecting the Facility Sample 
 Electronic files containing the FSF from each project 
area were sent to CDC using the CDC’s Secure Data 
Network (SDN). All files sent to CDC are stripped of 
identifying information for each facility; facilities are 
identified only by unique numeric facility identification (ID) 
number, assigned by the project area. Facility ID numbers 
for all project areas are made unique by adding a 4-digit 
project area code in front of the assigned 4-digit facility ID 
number. The number of facilities sampled in each project 
area varied from 25 in Houston and Los Angeles to 68 in 
California (Table 2). In Delaware a census of all 21 eligible 
facilities was used as the second stage sample. In other 
project areas, facilities were randomly sampled from among 
all facilities on the FSF. In the five states containing 
cities/counties that are separately funded for surveillance, a 
larger number of facilities was sampled in the second stage 
of sampling in order to provide more useful local data to the 
separately funded areas. Specifically, separate samples of 
facilities were selected within each of the six separately 
funded cities/counties as well as elsewhere in those states. 
 Of the 828 facilities sampled and eligible, 582 
participated. Because this was a strict probability sample, no 
replacement facilities were sampled. Furthermore, in those 
project areas with lower facility response rates the sample 
size was not increased because of the strict probability 
sampling protocol. This might be considered in future years. 
Facility participation rates ranged from 65% to 100%, with a 
median of 91.4%. 
(Table 1) contd….. 
Area of Residence  Measure of Size Region* PSU Stratum Size Sampled 
MAINE 492 NE Small No 
NEW HAMPSHIRE 506 NE Small No 
NEBRASKA 567 MW Small No 
WEST VIRGINIA 599 S Small No 
IOWA 686 MW Small No 
RHODE ISLAND 1058 NE Small No 
NEW MEXICO 1066 W Small No 
UTAH 1085 W Small No 
KANSAS 1113 MW Small No 
HAWAII 1247 W Small No 
DELAWARE 1531 S Small Yes 
*NE = Northeast; S = South; MW = Midwest; W = West. 
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THIRD STAGE OF SAMPLING 
 In the third and final stage of sampling, within each 
participating facility, eligible patients are sampled for 
inclusion in MMP. Participants are sampled from lists of 
patients seen at each facility during the PDP (i.e., January 1 
through April 30 of the data collection year). The selection 
of the patient sample is done in a manner that results in an 
equal probability of selection method sample at the patient 
level. This means that patients are sampled from each facility 
with a third-stage sampling probability which, when 
multiplied by the second-stage selection probability, results 
in the same overall selection probability for every patient 
selected in the project area. 
 Each patient sample is only used for one data collection 
cycle. A new sample of patients is drawn from the 
participating facilities in each data collection cycle. 
 HIV-infected patients who received all of their care from 
emergency departments or inpatient facilities are excluded 
from MMP, given that these facilities are excluded from the 
FSF. For sampled patients, in addition to information 













CALIFORNIA (rest of state) 68 56 28 69.6 500 
LOS ANGELES, CA 25 23 21 91.3 400 
SAN FRANCISCO, CA 30 29 24 89.7 400 
DELAWARE 21 20 18 90.0 400 
FLORIDA 60 49 31 85.7 754 
GEORGIA 49 35 25 91.4 400 
ILLINOIS (rest of state) 43 34 19 70.6 100 
CHICAGO, IL 41 26 19 92.3 400 
INDIANA 41 39 23 94.9 400 
MASSACHUSETTS 39 38 35 94.7 400 
MARYLAND 44 32 19 78.1 348 
MICHIGAN 53 40 31 87.5 401 
MISSISSIPPI 46 38 23 100.0 400 
NORTH CAROLINA 43 36 20 91.7 400 
NEW JERSEY 35 20 11 65.0 500 
NEW YORK (rest of state) 44 42 33 95.2 200 
NEW YORK CITY, NY 34 30 25 83.3 800 
OREGON 60 37 23 91.9 400 
PENNSYLVANIA (rest of state) 32 26 21 100.0 100 
PHILADELPHIA, PA 28 22 20 100.0 400 
PUERTO RICO 34 22 17 95.5 400 
SOUTH CAROLINA 31 16 14 93.8 400 
TEXAS (rest of state) 47 40 27 85.0 400 
HOUSTON, TX 25 20 13 65.0 400 
VIRGINIA 46 24 18 91.7 400 
WASHINGTON 40 34 24 79.4 400 
TOTAL 1059 828 582 87.2 10503 
      
   Mean 87.4  
   Min 65.0  
   Max 100.0  
   Median 91.4  
*Includes only facilities with patients sampled. 
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regarding their outpatient care, information on visits to 
emergency departments or inpatient facilities is also obtained 
during interviews, and/or may be documented in medical 
records. 
Constructing the Patient Sampling Frame 
 At the end of the PDP, health department MMP staff 
request a list from each sampled facility of all HIV-infected 
adults who received medical care (defined as any visit to the 
facility for medical care or prescription of medications, 
including refill authorizations and immunizations) during the 
PDP. Patients are eligible for inclusion on the patient 
sampling frame if they were HIV infected, at least 18 years 
of age at the beginning of the PDP, and received care at a 
sampled and participating facility during the PDP. 
 Facilities construct patient lists using International 
Classification of Diseases (ICD-9 or ICD-10) codes for 
procedures, tests or prescriptions during the PDP, or in 
smaller facilities by reviewing appointment logs. 
 Patients are eligible for selection only at their first 
reported visit to the facility during the PDP to ensure that 
multiple visits to the same facility do not lead to multiple 
opportunities for selection. As facilities use different 
mechanisms to identify eligible patients, the lists are not 
unduplicated across facilities. To account for multiplicity - 
multiple patient visits to different facilities during the PDP - 
the interview includes questions about the number of 
different facilities visited during the PDP to allow for the 
adjustment of the multiplicity of probability of selection in 
the weighting process. Without this, persons visiting more 
facilities would have higher probabilities of selection which 
could lead to estimation bias. 
 For each facility, the actual count of patients seen during 
the entire PDP derived from a facility’s patient list will differ 
from the selected best EPL used to construct the FSF. EPLs 
were obtained for a 4-month period, which should closely 
match the number of patients on the patient lists obtained for 
the 4 month PDP. 
Selecting the Patient Sample 
 Patient sampling is conducted as soon as all patient lists 
have been received from the participating facilities. The file 
containing lists of HIV-infected patients seen during the PDP 
at all participating facilities is used to select the patient 
sample. The selected participant ID numbers are returned to 
the project area via the CDC’s SDN after patient sampling 
has been completed; this set of participant IDs comprises the 
entire patient sample for the project area. 
 It was determined that 400 is the minimum sample size 
for a state to obtain total population estimates with an 
acceptable level of precision (assuming a moderate design 
effect [of between 2 and 4], or increase in variance of 
estimates due to using a multistage sampling design). This 
sample size was assigned to most of the states with the 
lowest AIDS prevalence. Sample sizes for states with 
moderate to high AIDS prevalence were determined based 
on the distribution of cases among the 20 sampled states and 
the 6 separately funded cities/counties in those states, in 
order to achieve a national sample size of approximately 
10,000. States that have large numbers of prevalent AIDS 
cases were allocated larger sample sizes (California 1300; 
Florida 800; Illinois 500; New Jersey 500; New York 1000; 
Pennsylvania 500; and Texas 800). These project area 
sample sizes will allow national estimates at an acceptable 
level of precision (assuming a moderate design effect) for 
subpopulations as small as 5% of the total population of 
interest. Table 2 outlines the patient sample size selected for 
each MMP project area. Although patient sample sizes of 
800 and 400 were selected for Florida and Maryland, 
respectively, errors in the estimation of patient loads during 
facility sampling frame construction resulted in reduced 
patient sample sizes in these areas. Patient selection was 
accomplished by systematic random sampling within 
facility. Changes in the probability of selection by 
oversampling in facilities with lower response rates were not 
attempted in order to maintain a constant probability of 
selection across all facilities in order to handle patient 
multiplicity. 
 It should be noted that in all stages of selection, the 
probability nature of the sample allows the computation of 
required probabilities of selection for selected patients: 
 Probability of Selection (Patienti) = P1 x P2 x P3x M, 
where 
P1 = the probability of selection for the state 
P2 = the probability of selection for the facility associated 
with the i
th
 selected patient 
P3 = the probability of selection for the i
th
 selected patient 
within the facility containing the patient. 
M = the number of facilities the patient reports visiting 
during the population definition period. 
PATIENT RECRUITMENT AND DATA 
COLLECTION 
 All patients selected for the sample should be recruited 
for enrollment in MMP. Persons selected during third-stage 
patient sampling may be offered enrollment through two 
general recruitment processes: MMP project area staff-
contact enrollment or facility-referred enrollment. The 
recruitment strategy varies according to facility preference 
and state or local project area IRB requirements. 
 For MMP staff-contact enrollment, facilities provide 
project area MMP staff with contact information for patients 
selected for recruitment. After obtaining patient contact 
information, the MMP staff contact selected patients to 
describe the project and offer enrollment. Scripts are used by 
all project areas to ensure a standardized recruitment 
approach within project areas. Patients who are eligible for 
enrollment and agree to participate are scheduled for an 
interview at a location that is convenient for the patient and 
meets the need for patient privacy. 
 Patients recruited through facility-referred enrollment are 
initially contacted by staff of the facility from which they 
were sampled. This may be done by telephone, in person, 
through chart insert and/or letter mailed from the facility. If 
by telephone or in person, the facility staff describe the 
project briefly and ask permission to provide contact 
information to MMP staff so that enrollment can be 
completed, or the facility staff ask the patient to contact the 
MMP staff. If recruitment takes place via chart insert or 
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letter, the documents will describe the project briefly and 
will provide contact information to enable the participant to 
reach MMP staff. 
 Patients who agree to participate and consent to the 
interview are asked questions by a trained interviewer. The 
interview includes questions about patients’ demographics, 
access to health care (including antiretroviral therapy), 
unmet needs for services, sexual behavior, drug and alcohol 
use, use of prevention services, and health and well-being. 
Following the interview, medical record abstraction is 
conducted on all sampled patients. Information obtained 
from medical charts by trained data abstractors includes 
patient demographics, insurance status, AIDS-defining and 
other illnesses, laboratory values, prescription of 
antiretroviral and other medications, and evidence of 
substance abuse. Many project area IRBs have determined 
that this abstraction can be done for all sampled patients as 
part of surveillance activities but in other project areas it can 
be done only if the patient agrees as part of the consent 
process. 
DISCUSSION 
 The experience of MMP demonstrates that it is possible 
to develop a credible national probability sample approach 
for HIV-infected persons receiving medical care in the 
United States. Unique challenges, such as the need to 
identify all providers of HIV care in each project area and 
the estimated number of patients each provider serves, were 
met by state, city and county health departments working 
through their existing surveillance systems and relationships 
they have built with providers of HIV care over the years. 
However, due to the size of the task of constructing facility 
sampling frames, the voluntary nature of the project (which 
allows providers and patients to refuse participation at any 
stage), and IRB and individual facility constraints on patient 
recruitment, project areas had varying success in 
constructing facility and patient sampling frames and 
recruiting sampled providers and patients in the 2007 pilot 
year. As subsequent MMP data collection cycles have been 
implemented, project areas have adopted best practices for 
facility and patient sampling frame construction, as well as 
provider and patient recruitment, which have resulted in 
improved efficiency and response rates. 
 Since patients receiving HIV care are only included on 
the patient sampling frame if they attended sampled facilities 
during the 4-month PDP, it is possible that patients who 
attend HIV care less frequently may be underrepresented. 
However, an analysis of HIV patients’ time to first annual 
HIV care visit found that for patients who had at least one 
HIV care visit in the previous year, 88% of patients had their 
first care visit within the first 4 months of the next year [6]. 
Therefore, the 4 month enrollment period should sufficiently 
reflect this patient population, even for those who do not 
frequently access care. 
 According to the Office of Management and Budget’s 
(OMB) Standards and Guidelines for Statistical Surveys, 
non-response bias analyses should be planned for when the 
unit response is expected to be below 80% [7]. Based on 
these OMB guidelines, the goal of MMP was to obtain 80% 
overall response rates at both the national and state levels. 
The overall response rate at the national level is the product 
of the project area (stage I), facility (stage II), and patient 
(stage III) response rates. Achieving an overall response rate 
of at least 80% is ambitious, particularly in a pilot year, and 
may be difficult to achieve even once MMP is being 
conducted at peak efficiency. Therefore, MMP has also 
pursued a policy of collecting minimal data about each 
patient sampled (sex, age, race/ethnicity, mode of exposure 
to HIV, most recent CD4 count) using state or local HARS 
data to allow for an effective non-response analysis. 
However, in some cases project area IRBs have not allowed 
this without patient permission, and some facilities have 
been unwilling to provide patient information for sampled 
patients who chose not to participate. 
 Despite these challenges we expect that MMP will be an 
important step forward in providing nationally representative 
statistics about HIV patients in care in the U.S. We also note 
that there are several nationally representative surveys that 
have achieved response rates below 80% and that still 
produce estimates that are respected and used by the 
scientific and policy communities. For example, the 
coverage rate for the HCSUS was 68% [8], and the response 
rate for the Behavioral Risk Factor Surveillance System, a 
state-based system of random digit dialed telephone surveys 
on health risk behaviors, has declined over the years; the 
response rate in 2006 was approximately 51% [9]. Once 
higher response rates are achieved, we could compare the 
demographics of the sampled patients with the demographics 
of persons living with HIV from the project area’s 
HIV/AIDS reporting system to ascertain the 
representativeness of their sample. 
 The MMP model, or similar models, could be adapted to 
enrolling and evaluating care and outcomes for a large range 
of chronic diseases for which comparative effectiveness data 
are desired. Sampling strategies can be adapted in response 
to priority research questions at the national level, or smaller 
geographic areas. Using such methods, it should be possible 
to gain an understanding of clinical effectiveness in the 
populations that are most relevant and most representative of 
the reference populations of greatest interest to health policy. 
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